Health FDA Approves First Oral RAS Inhibitor for Pancreatic Cancer, Doubling Survival August 26, 2026 The US Food and Drug Administration granted historic approval on August 26 to daraxonrasib (Rasonque), establishing it as a first-in-class targeted therapy for the most common form of pancreatic cancer.…
Health Revolutionary Cancer Drugs Show Promise in Doubling Survival Rates June 5, 2026 Breakthrough Medications Target Previously Untreatable Cancers Two experimental cancer drugs demonstrated remarkable results in recent clinical trials. These medications offer fresh hope for patients with advanced disease. Daraxonrasib, a RAS…